(19)
(11) EP 2 301 570 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(45) Mention of the grant of the patent:
27.01.2016 Bulletin 2016/04

(21) Application number: 10012296.9

(22) Date of filing: 31.12.2003
(51) International Patent Classification (IPC): 
A61K 51/10(2006.01)
C07K 16/28(2006.01)

(54)

Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated and conjugated antibodies, antibody combinations and fusion protein

Immunotherapie von B-zell Tumoren und Autoimmunerkrankungen unter Verwendung von unkonjugierten und konjugierten Antikörpern sowie Antikörperkombinationen und Fusionsproteinen

Immunothérapie s'appliquant aux tumeurs malignes des lymphocytes B et maladies auto-immunes utilisant des anticorps non conjugués et des anticorps conjugués, des combinaisons d'anticorps et des protéines de fusion


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 31.12.2002 US 437145 P

(43) Date of publication of application:
30.03.2011 Bulletin 2011/13

(62) Application number of the earlier application in accordance with Art. 76 EPC:
03786167.1 / 1578440

(73) Proprietor: Immunomedics, Inc.
Morris Plains, NJ 07950 (US)

(72) Inventors:
  • Goldenberg, David M.
    Morris Plains New Jersey 07950 (US)
  • Hansen, Hans
    Morris Plains New Jersey 07950 (US)

(74) Representative: Bohmann, Armin K. 
Bohmann Anwaltssozietät Nymphenburger Straße 1
80335 München
80335 München (DE)


(56) References cited: : 
WO-A-00/67796
WO-A-01/97855
WO-A-98/42378
WO-A-00/74718
WO-A-01/97858
WO-A1-00/67795
   
  • PRESS O W: "PROSPECTS FOR THE MANAGEMENT OF NON-HODGKIN'S LYMPHOMAS WITH MONOCLONAL ANTIBODIES AND IMMUNOCONJUGATES", CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 4, no. SUPPL 2, July 1998 (1998-07), pages S19-S26, XP000929567, ISSN: 1081-4442
  • SHIH L ET AL: "Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII JUL 2000 LNKD- PUBMED:10941903, vol. 49, no. 4-5, July 2000 (2000-07), pages 208-216, XP002619710, ISSN: 0340-7004
  • GRIFFITHS G L ET AL: "Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 11 JUN 1999 LNKD- PUBMED:10362149, vol. 81, no. 6, 11 June 1999 (1999-06-11), pages 985-992, XP002619711, ISSN: 0020-7136
  • GOVINDAN S V ET AL: "Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE DEC 2000 LNKD- PUBMED:11138697, vol. 41, no. 12, December 2000 (2000-12), pages 2089-2097, XP002619712, ISSN: 0161-5505
  • OCHAKOVSKAYA R ET AL: "Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2001 LNKD- PUBMED:11410483, vol. 7, no. 6, June 2001 (2001-06), pages 1505-1510, XP002619713, ISSN: 1078-0432
  • PRESS O W ET AL: "Immunotherapy of Non-Hodgkin's lymphomas.", HEMATOLOGY / THE EDUCATION PROGRAM OF THE AMERICAN SOCIETY OF HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM. UNITED STATES 2001, 2001, pages 221-240, XP002276291, ISSN: 1520-4391
  • TIETZE L F ET AL: "Carboranyl bisglycosides for the treatment of cancer by boron neutron capture therapy.", CHEMBIOCHEM: A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. GERMANY 4 MAY 2001, vol. 2, no. 5, 4 May 2001 (2001-05-04), pages 326-334, XP002276289, ISSN: 1439-4227
  • ILLIDGE T M ET AL: "RADIOIMMUNOTHERAPY OF CANCER: USING MONOCLONAL ANTIBODIES TO TARGET RADIOTHERAPY", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 6, no. 14, September 2000 (2000-09), pages 1399-1418, XP008020510, ISSN: 1381-6128
  • ONG G L ET AL: "Single-cell cytotoxicity with radiolabeled antibodies.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JAN 2001 LNKD- PUBMED:11205908, vol. 7, no. 1, January 2001 (2001-01), pages 192-201, XP002619714, ISSN: 1078-0432
  • PRESTA L G: "ENGINEERING ANTIBODIES FOR THERAPY", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON,FL, US, vol. 3, no. 3, 2002, pages 237-256, XP001105189, ISSN: 1389-2010
  • REDDI ELENA: "Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY, vol. 37, no. 3, 1997, pages 189-195, XP002276288, ISSN: 1011-1344
  • DE VITA SALVATORE ET AL: "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.", ARTHRITIS AND RHEUMATISM. UNITED STATES AUG 2002, vol. 46, no. 8, August 2002 (2002-08), pages 2029-2033, XP002276292, ISSN: 0004-3591
  • STEIN R ET AL: "CD74: A new candidate target for the immunotherapy of B-cell neoplasms", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18, 15 September 2007 (2007-09-15), pages 5556s-5563s, XP002510850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1167
  • L. Alinari ET AL: "Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma", Blood, vol. 117, no. 17, 28 April 2011 (2011-04-28), pages 4530-4541, XP055142749, ISSN: 0006-4971, DOI: 10.1182/blood-2010-08-303354
  • GUPTA PANKAJ ET AL: "Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas", BLOOD, vol. 119, no. 16, April 2012 (2012-04), pages 3767-3778, ISSN: 0006-4971(print)
  • Pankaj Gupta ET AL: "Abstract 4572: Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma", Cancer research, vol. 71, no. 8 Supplement, 15 April 2011 (2011-04-15), pages 4572-4572, XP055193106, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2011-4572
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).